Union adds to company’s goal of reaching net zero emissions by 2045.
Almac Group, a contract development and manufacturing organization (CDMO), announced it has officially joined the Science Based Targets Initiative (SBTi), which advocates for the best practices in science-based target settings. The company credits this move as the latest step taken with the objective of reaching net zero emissions by 2045.
The collaboration, which is headed by CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the Worldwide Fund for Nature (WWF), is one of multiple steps Almac Group has taken to reach net zero. Other efforts include the expansion of accreditations with the International Standard Organization (ISO), accepted as the gold standard in health, safety, and environmental activity.
“Developing science-based targets for the reduction of greenhouse gas emissions is a crucial next step and demonstrates the commitment to our environmental responsibilities at Almac,” said Niall Harkin, executive director, Almac Group. “At Almac, we see transparency and alignment to internationally recognized standards as essential in demonstrating our commitment to making a measurable and positive impact on our planet.Signing up to SBTi, coupled with our latest ISO certifications represent an essential part of Almac’s plan to reach net-zero by 2045 and we are proud to mark these milestones in our progress.”
Reference: Almac Group signs up to Science Based Targets initiative. (2023, July 4).
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.